RSNA In Brief
This article was originally published in The Gray Sheet
Executive Summary
GE/Amersham Health: Firms' research agreement inked Nov. 27 will focus initially on radiopharmaceuticals to be used with positron emission tomography (PET) in diagnosis of Parkinson's disease. FDG and FDOPA are among pharmaceuticals under study. GE Medical Systems also announces FDA approval for its sixteen-slice PET system, to be launched in the U.S. next year...
You may also be interested in...
R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development
R2 Technologies' proposed initial public offering will fund development of the LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computerized tomography (CT) scans, and shore up its current mammography CAD business
R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development
R2 Technologies' proposed initial public offering will fund development of the LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computerized tomography (CT) scans, and shore up its current mammography CAD business
Fischer Taking Chance With SenoScan 510(k), Leaving PMA Route Open
Fischer Imaging's premarket notification submission for the SenoScan full-field digital mammography system is readily convertible into a PMA, should FDA reject the 510(k) approach for the device, as the agency has done in the past.